Med24
peptide-development 1. 10. 2026 • 2 min read • BMJ open

Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues

Objective As obesity and diabetes are on the verge of an alarming growth, so is the use of tirzepatide, a novel dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 (GLP-1) receptor agonist (RA) and currently the most effective weight loss-drug. This research aimed to identify reporting patterns...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This research aimed to identify reporting patterns related to suboptimal therapeutic outcomes and tirzepatide-related drug-use issues by analyzing data from the EudraVigilance (EV) database. The study utilized descriptive and disproportionality analyses of individual case safety reports involving tirzepatide, comparing them with other GLP-1 receptor agonists (RAs) within the overall dataset and specifically within healthcare professional (HP) reports.

Key Clinical Findings

The analysis encompassed reports from both healthcare professionals and non-healthcare professionals. Key outcome measures involved reporting odds ratios (RORs) with 95% confidence intervals (CIs) for selected Preferred Terms (PTs) related to drug-use issues. Frequently reported PTs included ‘Off-label use’ (n=1521), ‘Drug ineffective’ (n=425), and ‘Off-label use device’ (n=99).

Sponsored content

Within the overall dataset, reports involving tirzepatide demonstrated lower reporting odds for the PT ‘Drug ineffective’ compared to reports involving liraglutide (ROR 0.61, 95% CI 0.54 to 0.70), dulaglutide (ROR 0.72, 95% CI 0.63 to 0.82), exenatide (ROR 0.78, 95% CI 0.67 to 0.92) and semaglutide (ROR 0.81, 95% CI 0.72 to 0.91). However, in HP reports, no difference in reporting odds was observed between tirzepatide and semaglutide regarding this PT. A different pattern was observed for ‘off-label use’ in the full dataset, with higher reporting odds for tirzepatide compared to lixisenatide, dulaglutide and liraglutide, but lower reporting odds compared to semaglutide (ROR 0.52, 95% CI 0.49 to 0.55). Furthermore, a higher reporting odd for the PT ‘off-label use of device’ was observed for tirzepatide versus semaglutide (ROR 43.47, 95% CI 16.00 to 118.13) in the overall reports; however, this finding should be interpreted with caution given the wide confidence interval. This study complements existing evidence from clinical trials and current clinical practice.

Original Scientific Source
BMJ open
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Advertisement